2023
Mapping Lesion-Related Epilepsy to a Human Brain Network
Schaper F, Nordberg J, Cohen A, Lin C, Hsu J, Horn A, Ferguson M, Siddiqi S, Drew W, Soussand L, Winkler A, Simó M, Bruna J, Rheims S, Guenot M, Bucci M, Nummenmaa L, Staals J, Colon A, Ackermans L, Bubrick E, Peters J, Wu O, Rost N, Grafman J, Blumenfeld H, Temel Y, Rouhl R, Joutsa J, Fox M. Mapping Lesion-Related Epilepsy to a Human Brain Network. JAMA Neurology 2023, 80: 891-902. PMID: 37399040, PMCID: PMC10318550, DOI: 10.1001/jamaneurol.2023.1988.Peer-Reviewed Original ResearchConceptsRisk of epilepsyLesion locationBrain regionsPoststroke epilepsyControl patientsSeizure controlBrain lesionsIndependent cohortBrain networksLesion typeBrain stimulation sitesLesion network mappingLesion-related epilepsyImproved seizure controlDrug-resistant epilepsyCase-control studyBrain stimulation therapyHuman brain networksSpecific brain regionsDifferent lesion typesSpecific brain networksBasal gangliaVascular territoriesStimulation therapyMAIN OUTCOME
2019
One-year changes in brain microstructure differentiate preclinical Huntington's disease stages
Pflanz C, Charquero-Ballester M, Majid D, Winkler A, Vallée E, Aron A, Jenkinson M, Douaud G. One-year changes in brain microstructure differentiate preclinical Huntington's disease stages. NeuroImage Clinical 2019, 25: 102099. PMID: 31865023, PMCID: PMC6931230, DOI: 10.1016/j.nicl.2019.102099.Peer-Reviewed Original ResearchConceptsOnset of symptomsPreclinical stageDisease stageMean diffusivityHuntington's diseaseGender-matched healthy controlsOnly clinical measurePosterior basal gangliaDistinct pathophysiological mechanismsOptimal therapeutic windowOne-year changeSignificant differencesPreclinical Huntington's diseasePresymptomatic Huntington's diseaseNeurodegenerative phaseNeuroinflammatory processesMotor scoresPathophysiological mechanismsBasal gangliaDisease progressionHealthy controlsHuntington's disease stagesCorpus callosumTreatment responseClinical measures